Table 4

The incidence rate ratios (IRR) of general practitioner (GP) consultations, respiratory events, and adverse-medication events, in the risk period after an inhaler switch compared with stable periods

EventNumber of patientsNumber of events in
3-month risk period
Number of events in control periodIRR95% CI
GP consultation50 289143 602926 9911.000.99 to 1.01
Non-specific respiratory51 65927 772187 6180.960.94 to 0.97
Adverse-medication325857335201.060.97 to 1.15
  • Switches could be between brand-to-generic, brand-to-brand, generic-to-generic or generic-to-brand.

  • DPI, dry powdered inhaler; MDI, metered-dose inhaler.